来自MSN1 个月
LEXX: IRB Approval Clears Way for GLP-1 Study #5
Lexaria Bioscience Corporation (NASDAQ:LEXX) reported fiscal first quarter 2025 results along with program updates, progress in its GLP-1 trials, a capital raise and final preparations for the ...
Lexaria Bioscience股价触及52周新低1.37美元
在充满挑战的市场环境下，Lexaria Bioscience Corp. (LEXX)股价触及52周新低，达到1.37美元。根据 InvestingPro 分析，该公司市值为2545万美元，市净率为2.6倍，目前估值处于合理水平。这次最新跌势凸显了公司过去一年的显著下滑，Lexaria Bioscience一年来股价变动为-51.67%。尽管公司保持29.64的强劲流动比率，且现金多于债务，但 ...
Nasdaq4 年
Lexaria Bioscience Corp. Common Stock (LEXX) After-Hours
Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result, these ...
The Globe and Mail4 个月
Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm
KELOWNA, BC / ACCESS Newswire / February 24, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces it has ...
Nasdaq3 个月
Lexaria Bioscience Corp. Common Stock (LEXX)
Real time quote data is not available at this time. *Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green ...
The Globe and Mail3 个月
The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience
KELOWNA, BC / ACCESS Newswire / February 27, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides the ...